Clinical Trials Logo

Clinical Trial Summary

The protocol is to draw peripheral blood from healthy volunteers for in vitro studies. The aims of these in vitro studies are to determine the cellular and intracellular mechanisms by which hypertonic saline and ATP release regulate neutrophil and lymphocyte functions.


Clinical Trial Description

The proper regulation of leukocyte function is critical for immune defense and to prevent autoimmune diseases. Many aspects of immune cell regulation are unknown. A better understanding could lead to novel therapeutic approaches to improve immune function in patients suffering from various diseases.

The investigators have found that hypertonic conditions regulate leukocyte functions through feedback mechanisms involving ATP release and purinergic receptors. The purpose of the proposed protocol is to obtain access to peripheral blood from healthy volunteers to study these complex regulatory mechanisms in more detail. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03027232
Study type Observational
Source Beth Israel Deaconess Medical Center
Contact
Status Completed
Phase
Start date January 2007
Completion date December 15, 2017

See also
  Status Clinical Trial Phase
Completed NCT03242395 - PRIME: Cognitive Outcome Following Major Burns N/A
Recruiting NCT04032626 - MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients Phase 2
Completed NCT04002219 - Efficacy Evaluation of the Mushroom Beverage on Emotion Regulation N/A
Not yet recruiting NCT06177028 - MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Phase 2
Active, not recruiting NCT05515640 - Dysautonomia and Systemic Interactions in Traumatic Brain Injury